Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Long-Term Investments (2016 - 2025)

Historic Long-Term Investments for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $1.6 billion.

  • United Therapeutics' Long-Term Investments rose 2250.27% to $1.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 2250.27%. This contributed to the annual value of $1.5 billion for FY2024, which is 2275.11% down from last year.
  • As of Q3 2025, United Therapeutics' Long-Term Investments stood at $1.6 billion, which was up 2250.27% from $1.9 billion recorded in Q2 2025.
  • Over the past 5 years, United Therapeutics' Long-Term Investments peaked at $2.1 billion during Q3 2023, and registered a low of $1.3 billion during Q3 2024.
  • Its 5-year average for Long-Term Investments is $1.6 billion, with a median of $1.6 billion in 2022.
  • As far as peak fluctuations go, United Therapeutics' Long-Term Investments soared by 6514.98% in 2021, and later crashed by 3791.73% in 2024.
  • Quarter analysis of 5 years shows United Therapeutics' Long-Term Investments stood at $1.6 billion in 2021, then fell by 20.23% to $1.3 billion in 2022, then skyrocketed by 45.1% to $1.9 billion in 2023, then dropped by 22.75% to $1.5 billion in 2024, then increased by 6.24% to $1.6 billion in 2025.
  • Its Long-Term Investments stands at $1.6 billion for Q3 2025, versus $1.9 billion for Q2 2025 and $1.7 billion for Q1 2025.